.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,898,724

« Back to Dashboard

Claims for Patent: 4,898,724

Title: Organis amine phosphonic acid complexes for the treatment of calcific tumors
Abstract:Particle-emitting radionuclides, e.g. Samarium-153, have been complexed with organic aminoalkylenephosphonic acids wherein the nitrogen and phosphorus are interconnected by an alkylene group or substituted alkylene group. These complexes have been found useful in compositions for the therapeutic treatment of calcific tumors in animals.
Inventor(s): Simon; Jaime (Angleton, TX), Wilson; David A. (Richwood, TX), Volkert; Wynn A. (Columbia, MO), Troutner; David E. (Columbia, MO), Goeckeler; William F. (Midland, MI)
Assignee: The Dow Chemical Company (Midland, MI)
Application Number:07/050,263
Patent Claims: 1. A composition comprising (1) a complex which comprises Sm-153 and at least one of an aminophosphonic acid or a physiologically acceptable salt thereof wherein the aminophosphonic acid is selected from the group consisting of ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, hydroxyethylethylenediaminetrimethylenephosphonic acid, tris(2-aminoethyl)aminehexamethylenephosphonic acid, bis(aminoethyl)piperazinetetramethylenephosphonic acid, and (1-carboxy)ethylenediaminetetramethylenephosphonic acid and (2) at least one of the above aminophosphonic acids, or a physiologically acceptable salt thereof, in excess of that required to make the complex, and wherein the resulting composition is therapeutically effective.

2. The composition of claim 1 wherein a physiologically acceptable liquid carrier is present.

3. The composition of claim 2 wherein the physiologically acceptable liquid carrier is water and the resulting solution is adjusted to have a pH of about 7 to about 8.

4. A composition comprising (1) a complex which comprises Sm-153 and ethylenediaminetetramethylenephosphonic acid or a physiologically acceptable salt thereof and (2) ethylenediaminetetramethylenephosphonic acid or a physiologically acceptable salt thereof, in excess of that required to make the complex, and wherein the resulting composition is therapeutically effective.

5. The composition of claim 4 wherein a physiologically acceptable liquid carrier is present.

6. The composition of claim 5 wherein the physiologically acceptable liquid carrier is water and the resulting solution is adjusted to have a pH of about 7 to about 8.

7. A method for the therapeutic treatment of an animal having one or more calcific tumors which comprises administering to said animal a therapeutically effective amount of a composition comprising (1) a complex which comprises SM-153 and at least one of an aminophosphonic acid or a physiologically acceptable salt thereof wherein the aminophosphonic acid is selected from the group consisting of ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, hydroxyethylethylenediaminetrimethylenephosphonic acid, tris(2-aminoethyl)aminehexamethylenephosphonic acid, bis(aminoethyl)piperazinetetramethylenephosphonic acid, and (1-carboxy)ethylenediaminetetramethylenephosphonic acid and (2) at least one of the above aminophosphonic acids, or a physiologically acceptable salt thereof, in excess of that required to make the complex.

8. The method of claim 7, wherein the animal is a human.

9. The method of claim 7 wherein a physiologically acceptable liquid carrier is present.

10. The method of claim 9 wherein the physiologically acceptable liquid carrier is water and the resulting solution is adjusted to have a pH of about 7 to about 8.

11. A method for the therapeutic treatment of an animal having one or more calcific tumors which comprises administering to said animal a therapeutically effective amount of a composition comprising (1) a complex which comprises Sm-153 and ethylenediaminetetramethylenephosphonic acid or a physiologically acceptable salt thereof and (2) ethylenediaminetetramethylenephosphonic acid or a physiologically acceptable salt thereof, in excess of that required to make the complex.

12. The method of claim 11 wherein the animal is a human.

13. The method of claim 11 wherein a physiologically acceptable liquid carrier is present.

14. The method of claim 13 wherein the physiologically acceptable liquid carrier is water and the resulting solution is adjusted to have a pH of about 7 to about 8.

15. A sterile composition suitable for administration to a mammal comprising (1) a complex which comprises Sm-153 and at least one of an aminophosphonic acid or a physiologically acceptable salt thereof wherein the aminophosphonic acid is selected from the group consisting of ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid hydroxyethylethylenediaminetrimethylenephosphonic acid, tris(2-aminoethyl)aminehexamethylenephosphonic acid, bis(aminoethyl)piperazinetetramethylenephosphonic acid, and (1-carboxy)ethylenediaminetetramethylenephosphonic acid and (2) at least one of the above aminophosphonic acids, or a physiologically acceptable salt thereof, in excess of that required to make the complex, and wherein the resulting composition is therapeutically effective and wherein the Sm-153 in dosage form is present in an amount containing at least 0.02 mCi per kilogram of body weight of said mammal.

16. The composition of claim 15 wherein a physiologically acceptable liquid carrier is present.

17. The composition of claim 16 wherein the physiologically acceptable liquid carrier is water and the resulting solution is adjusted to have a pH of about 7 to about 8.

18. A sterile composition suitable for administration to a mammal comprising (1) a complex which comprises Sm-153 and ethylenediaminetetramethylenephosphonic acid or a physiologically acceptable salt thereof and (2) ethylenediaminetetramethylenephosphonic acid or a physiologically acceptable salt thereof, in excess of that required to make the complex, and where in the resulting composition is therapeutically effective and wherein the Sm-153 in dosage form is present in an amount containing at least 0.02 mCi per kilogram of body weight of said mammal.

19. The composition of claim 18 wherein a physiologically acceptable liquid carrier is present.

20. The composition of claim 19 wherein the physiologically acceptable liquid carrier is water and the resulting solution is adjusted to have a pH of about 7 to about 8.

21. A method for the therapeutic treatment of an animal having bone pain which comprises administering to said animal a therapeutically effective amount of a composition comprising (1) a complex which comprises Sm-153 and at least one of an aminophosphonic acid or a physiologically acceptable salt thereof wherein the aminophosphonic acid is selected from the group consisting of ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, hydroxyethylethylenediaminetrimethylenephosphonic acid, tris(2-aminoethyl)aminehexamethylenephosphonic acid, bis(aminoethyl)piperazinetetramethylenephosphonic acid, and (1-carboxy)ethylenediaminetetramethylenephosphonic and (2) at least one of the above aminophosphonic acids, or a physiologically acceptable salt thereof, in excess of that required to make the complex.

22. The method of claim 21 wherein a physiologically acceptable liquid carrier is present.

23. The method of claim 22 wherein the physiologically acceptable liquid carrier is water and the resulting solution is adjusted to have a pH of about 7 to about 8.

24. A method for the therapeutic treatment of an animal having bone pain which comprises administering to said animal a therapeutically effective amount of a composition comprising (1) a complex which comprises Sm-153 and ethylenediaminetetramethylenephosphonic acid or a physiologically acceptable salt thereof and (2) ethylenediaminetetramethylenephosphonic acid or a physiologically acceptable salt thereof, in excess of that required to make the complex.

25. The method of claim 24 wherein a physiologically acceptable liquid carrier is present.

26. The method of claim 25 wherein the physiologically acceptable liquid carrier is water and the resulting solution is adjusted to have a pH of about 7 to about 8.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc